Advanced Cholangiocarcinoma: A New Era of Mechanisms and Management

To participate in this activity, please:

Survival outcomes for advanced cholangiocarcinoma remain suboptimal, despite first-line treatment with cytotoxic chemotherapy. Greater understanding of the pathobiology of cholangiocarcinoma has illuminated a variety of treatment targets, leading to several treatment advances. In this 0.5-hour activity, medical oncologist Lipika Goyal, MD, MPhil, discusses key concepts in navigating through the selection and use of these agents, including managing associated adverse events, helping shape the management of advanced cholangiocarcinoma to optimize patient care.

Course Credit:

0.50 AMA PRA Category 1 CreditsTM

Dates:

Opens: 2023-10-25
Closes: 2024-10-25

Target Audience:

This activity is intended for oncologists, gastroenterologists, pathologists, and other healthcare providers caring for patients with cholangiocarcinoma.

This activity is supported by independent educational grants from Incyte and Taiho Oncology, Inc.

    Presenting Faculty

  • Lipika Goyal, MD, MPhil

    Associate Professor of Medicine
    Stanford School of Medicine
    Director of Gastrointestinal Oncology
    Stanford Cancer Institute
    Palo Alto, California